Market Research Report
Norovirus infection - Pipeline Insight, 2021
|Norovirus infection - Pipeline Insight, 2021|
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
DelveInsight's, "Norovirus infection - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Norovirus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Norovirus infection typically causes acute gastroenteritis. It is also a common cause of food poisoning and is usually related to consumption of undercooked shellfish. People can get norovirus infection from having direct contact with an infected person, consuming contaminated food or water, or by touching contaminated surfaces. Norovirus can also cause outbreaks of acute gastroenteritis in settings where people are staying close together such as schools, elderly homes, hotels, play facilities and cruise ships. The disease affects people of all age groups and tends to be more common during winter. The virus is previously known as 'Norwalk-like viruses'.
"Norovirus infection - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Norovirus infection pipeline landscape is provided which includes the disease overview and Norovirus infection treatment guidelines. The assessment part of the report embraces, in depth Norovirus infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Norovirus infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Norovirus infection R&D. The therapies under development are focused on novel approaches to treat/improve Norovirus infection.
This segment of the Norovirus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection. To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects.
Vaxart is developing a bivalent tablet vaccine for norovirus, a leading cause of acute viral gastroenteritis and food-borne disease in the U.S. and Europe. Vaxart has completed two Phase 1 clinical trials with its monovalent oral tablet vaccine based on the GI.1 norovirus strain, demonstrating its norovirus tablet vaccine was well tolerated and generated broad systemic and mucosal immune responses. In the recently completed clinical Phase 1b dose-optimization study in healthy adults, in which Vaxart evaluated four different dosing regimens, all vaccine recipients (100%) in the high-dose group responded as measured by a significant increase in norovirus specific B cells of both IgA and IgG subtypes. In the same group, there was at least a two-fold increase of norovirus specific antibody titers in serum in more than 90% of recipients 56 days after dosing.
This segment of the report provides insights about the different Norovirus infection drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 8+ key companies which are developing the therapies for Norovirus infection. The companies which have their Norovirus infection drug candidates in the most advanced stage, i.e. phase II include, HilleVax.
DelveInsight's report covers around 8+ products under different phases of clinical development like:
Norovirus infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Norovirus infection therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Norovirus infection drugs.